<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Phase II study of YNK01 (<z:chebi fb="0" ids="28680">1-beta-D-arabinofuranosylcytosine</z:chebi>-5'-stearylphosphate), a derivative of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, on <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> was conducted by multi-institutional cooperative group </plain></SENT>
<SENT sid="1" pm="."><plain>YNK01 was administered orally at dose of 100-300 mg/body/day for more than 2 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>The number of registered and evaluated patients were 211 and 156, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Of 23 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> myelogeneous <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 2 complete response (CR), one partial response (PR) were observed (CR + PR: 13.0%) </plain></SENT>
<SENT sid="4" pm="."><plain>Hypoplastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (1/4: 25%), <z:hpo ids='HP_0011009'>acute</z:hpo> unclassified <z:hpo ids='HP_0001909'>leukemia</z:hpo> (1/1: 100%) </plain></SENT>
<SENT sid="5" pm="."><plain>Of 45 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 2CRs, 6 good response (GR) and 5PRs were observed (CR + PR: 28.9%) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> developing after a prior history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (5/17: 29.4%), <z:mp ids='MP_0005481'>CML</z:mp>-BC (2/9: 22.2%) </plain></SENT>
<SENT sid="7" pm="."><plain>Of 19 patients with <z:mp ids='MP_0005481'>CML</z:mp>, 9 achieved CR, 3 achieved PR (63.2%) </plain></SENT>
<SENT sid="8" pm="."><plain>Of 11 patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, 4 achieved CR, 5 achieved PR (81.8%) </plain></SENT>
<SENT sid="9" pm="."><plain>Of 6 patients with essential <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo>, 2 achieved CR, one achieved PR (50%) </plain></SENT>
<SENT sid="10" pm="."><plain>The major adverse effects included gastrointestinal toxicities such as <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, <z:hpo ids='HP_0002039'>anorexia</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and elevation of GOT and GPT which were tolerable and reversible </plain></SENT>
<SENT sid="11" pm="."><plain>This study indicates that YNK01 is a useful agent against <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, especially <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in T, CMMoL </plain></SENT>
</text></document>